MetaCap

Fractyl Health Inc. (GUTS)

NASDAQ: GUTSHealth CareMedical/Dental InstrumentsUSD

0.82-0.1353 (-14.16%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GUTS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$10.88M
EPS (TTM)
-$3.14
52-week range
0.784 – 29.34
Day range
0.784 – 0.9698
Volume / Avg
333.60K / 504.39K
Beta
—

52-week range

$0.784$29.34

GUTS stock today

Shares of Fractyl Health (GUTS) finished lower on Nov 20 at $0.82, a drop of 14.16% or $0.1353 per share, versus the S&P 500's 3.70% decline. Shares are 97.2% below their 52-week high of $29.34, set on Dec 12, 2025 and 4.6% above the 52-week low of $0.784, near the bottom of the past year's range. GUTS is down 96.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 95.1%.

Fractyl Health has posted a net loss over the last twelve months (EPS of -$3.14), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Fractyl Health

Company profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.

Industry
Medical/Dental Instruments
CEO
Dr. Harith Rajagopalan M.D., Ph.D.
Headquarters
Burlington, MA
Employees
100
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Fractyl Health generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Fractyl Health reported a net loss of $141.0 million, compared with a loss of $68.7 million a year earlier. Diluted earnings per share came in at -$1.86.

Fractyl Health annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$0$93.00K$120.00K
Growth-100.00%-22.50%—
Net income$-140.95M$-68.69M$-77.09M
EPS (diluted)$-1.86$-1.62$-45.29

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$60.40+7265.85%

  • Strong buy 0
  • Buy 6
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $24.00High $96.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-4.20 vs $-1.59
Surprise
-164.15%

GUTS news

All GUTS news

Fractyl Health peers

Health Care sector
GUTS peer companies
CompanyPrice% ChgMarket capCompare
FEMYFemasys Inc.1.240.00%$10.73Mvs GUTS
PAVMPAVmed Inc.1.14-5.42%$9.08Mvs GUTS
SNWVSANUWAVE Health Inc.1.50-5.66%$12.90Mvs GUTS
AEMDAethlon Medical Inc.5.46+12.81%$8.78Mvs GUTS
CTSOCytosorbents Corporation4.16-18.91%$13.12Mvs GUTS
PLSMPulsenmore Ltd.1.29-4.44%$8.39Mvs GUTS
SINTSiNtx Technologies Inc.1.10-8.74%$8.31Mvs GUTS
SKYASkyAI Inc.2.18-45.50%$7.82Mvs GUTS

Indexes, lists and sector

Fractyl Health stock FAQ

What is Fractyl Health's stock price today?

GUTS last traded at $0.82 as of Nov 20, 4:00 PM EST, down 14.16% on the day. Prices are delayed at least 15 minutes.

Does Fractyl Health pay a dividend?

No. Fractyl Health does not currently pay a regular cash dividend.

Who is Fractyl Health's CEO?

Dr. Harith Rajagopalan M.D., Ph.D. is the chief executive officer of Fractyl Health Inc., which has about 100 employees.

Has GUTS ever split its stock?

Yes. The most recent GUTS stock split was a 1-for-12 split on Oct 5, 2026.

What is the GUTS 52-week high?

The 52-week high for GUTS is $29.34 and the 52-week low is $0.784. The stock is currently 97.2% below its high.

Compare GUTS